Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes
Early diagnosis of the pathological cause, if any, of short stature in children can lead to prompt intervention with recombinant growth hormone (rGH) treatment, potentially allowing them to achieve their true genetic height potential. However, it is crucial to identify children most likely to benefi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1516967/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849735682683043840 |
|---|---|
| author | Sara Salem Al Jneibi Fatima Taha Marwa Hammouri Zahraa Allami Stefan Weber Jamal Aljubeh Sareea Al Remeithi |
| author_facet | Sara Salem Al Jneibi Fatima Taha Marwa Hammouri Zahraa Allami Stefan Weber Jamal Aljubeh Sareea Al Remeithi |
| author_sort | Sara Salem Al Jneibi |
| collection | DOAJ |
| description | Early diagnosis of the pathological cause, if any, of short stature in children can lead to prompt intervention with recombinant growth hormone (rGH) treatment, potentially allowing them to achieve their true genetic height potential. However, it is crucial to identify children most likely to benefit from rGH treatment.MethodsThis cross-sectional, retrospective study provides a broad overview of rGH prescribing patterns and evaluates both short- and long-term treatment outcomes in children treated at the Pediatric Endocrinology Clinic, Sheikh Khalifa Medical City, Abu Dhabi, UAE, between January 2011 and December 2022. One- and three-year outcome data for children treated with rGH for different diagnoses of short stature were assessed.ResultsIdiopathic short stature (ISS) accounted for 34.8% of the cases for which rGH was prescribed. A significant response [mean height gain of ≥0.3 standard deviation score (SDS)/year] was seen across all assessed short-stature diagnoses, with the highest gain seen in the growth hormone deficiency (GHD) diagnosis group at the 1-year and 3-year treatment time points. More than 90% of the children diagnosed with GHD and ISS achieved normal final adult height. Younger age at rGH initiation, lower height SDS at baseline, and pre-pubertal status were associated with better outcomes post 1 and 3 years of rGH therapy. Greater response at 1 year of rGH therapy was associated with better final adult height outcome.ConclusionsISS was the most common indication for which rGH was prescribed in this study. A favorable increment in the height SDS of the rGH-treated children during their 1- and 3-year follow-ups was observed. Age, pubertal status, baseline height SDS, and rGH response at 1 year were directly associated with significantly improved short- and long-term response to rGH treatment. These findings provide a broad overview of the baseline and therapeutic response characteristics of rGH-treated children with short stature in the UAE and can help in optimizing and personalizing treatment strategies. |
| format | Article |
| id | doaj-art-8792d998f7264a61aaa01e1f7890c205 |
| institution | DOAJ |
| issn | 2296-2360 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj-art-8792d998f7264a61aaa01e1f7890c2052025-08-20T03:07:28ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-05-011310.3389/fped.2025.15169671516967Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomesSara Salem Al JneibiFatima TahaMarwa HammouriZahraa AllamiStefan WeberJamal AljubehSareea Al RemeithiEarly diagnosis of the pathological cause, if any, of short stature in children can lead to prompt intervention with recombinant growth hormone (rGH) treatment, potentially allowing them to achieve their true genetic height potential. However, it is crucial to identify children most likely to benefit from rGH treatment.MethodsThis cross-sectional, retrospective study provides a broad overview of rGH prescribing patterns and evaluates both short- and long-term treatment outcomes in children treated at the Pediatric Endocrinology Clinic, Sheikh Khalifa Medical City, Abu Dhabi, UAE, between January 2011 and December 2022. One- and three-year outcome data for children treated with rGH for different diagnoses of short stature were assessed.ResultsIdiopathic short stature (ISS) accounted for 34.8% of the cases for which rGH was prescribed. A significant response [mean height gain of ≥0.3 standard deviation score (SDS)/year] was seen across all assessed short-stature diagnoses, with the highest gain seen in the growth hormone deficiency (GHD) diagnosis group at the 1-year and 3-year treatment time points. More than 90% of the children diagnosed with GHD and ISS achieved normal final adult height. Younger age at rGH initiation, lower height SDS at baseline, and pre-pubertal status were associated with better outcomes post 1 and 3 years of rGH therapy. Greater response at 1 year of rGH therapy was associated with better final adult height outcome.ConclusionsISS was the most common indication for which rGH was prescribed in this study. A favorable increment in the height SDS of the rGH-treated children during their 1- and 3-year follow-ups was observed. Age, pubertal status, baseline height SDS, and rGH response at 1 year were directly associated with significantly improved short- and long-term response to rGH treatment. These findings provide a broad overview of the baseline and therapeutic response characteristics of rGH-treated children with short stature in the UAE and can help in optimizing and personalizing treatment strategies.https://www.frontiersin.org/articles/10.3389/fped.2025.1516967/fullgrowth hormoneshort staturerecombinantchildrendeficiencyendocrine |
| spellingShingle | Sara Salem Al Jneibi Fatima Taha Marwa Hammouri Zahraa Allami Stefan Weber Jamal Aljubeh Sareea Al Remeithi Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes Frontiers in Pediatrics growth hormone short stature recombinant children deficiency endocrine |
| title | Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes |
| title_full | Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes |
| title_fullStr | Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes |
| title_full_unstemmed | Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes |
| title_short | Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes |
| title_sort | recombinant growth hormone therapy in children with short stature in abu dhabi a cross sectional study of indications and treatment outcomes |
| topic | growth hormone short stature recombinant children deficiency endocrine |
| url | https://www.frontiersin.org/articles/10.3389/fped.2025.1516967/full |
| work_keys_str_mv | AT sarasalemaljneibi recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes AT fatimataha recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes AT marwahammouri recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes AT zahraaallami recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes AT stefanweber recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes AT jamalaljubeh recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes AT sareeaalremeithi recombinantgrowthhormonetherapyinchildrenwithshortstatureinabudhabiacrosssectionalstudyofindicationsandtreatmentoutcomes |